Eli Lilly & Co. and Bristol-Myers Squibb Co. See FDA Withdrawal of Approval for Estrogen-Androgen Combination Drugs

Summary

The FDA is withdrawing approval of three new drug applications for estrogen-androgen combination drugs, products developed by Eli Lilly & Co. and Bristol-Myers Squibb Co., which are no longer being marketed, following requests from both companies to withdraw the applications and waive a hearing.